Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –
Vaxart r&d expenses
Research and development expenses are spending on new products and technology.
Vaxart's R&D Expenses for the twelve months ending Sep 30, 2026 was $131.15M, down 26.8% year over year. For fiscal 2025 it was $201.58M, up 171.6% from the year before. Over ten years it grew 27.7% a year on average. The highest annual figure on record is $201.58M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.58M | +171.6% |
| FY2024 | Dec 31, 2024 | $74.21M | +8.9% |
| FY2023 | Dec 31, 2023 | $68.14M | -15.9% |
| FY2022 | Dec 31, 2022 | $81.05M | +66.3% |
| FY2021 | Dec 31, 2021 | $48.75M | +145.4% |
| FY2020 | Dec 31, 2020 | $19.86M | +36.6% |
| FY2019 | Dec 31, 2019 | $14.54M | -15.8% |
| FY2018 | Dec 31, 2018 | $17.28M | -34.3% |
| FY2016 | Jun 30, 2016 | $26.30M | +32.8% |
| FY2015 | Jun 30, 2015 | $19.80M | +13.1% |
| FY2014 | Jun 30, 2014 | $17.50M | -12.1% |
| FY2013 | Jun 30, 2013 | $19.90M | -17.4% |
| FY2012 | Jun 30, 2012 | $24.10M | +46.1% |
| FY2009 | Dec 26, 2009 | $16.49M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $22.83M | -69.9% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $33.75M | -32.1% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $29.41M | -4.3% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $45.15M | +99.3% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $75.95M | +404.1% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $49.74M | +184.5% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $30.74M | +61.7% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $22.65M | +54.1% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $15.07M | +0.4% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $17.48M | -7.1% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $19.01M | -3.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $14.71M | -28.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $15.00M | -33.2% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $18.81M | -5.6% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $19.62M | +7.8% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $20.46M | +31.7% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $22.47M | +81.0% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $19.93M | +85.6% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $18.20M | +80.7% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $15.53M | +80.8% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $12.41M | +168.8% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $10.74M | +110.0% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $10.07M | +553.2% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $8.59M | +161.0% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $4.62M | +24.3% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $5.11M | +38.0% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $1.54M | -59.7% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $3.29M | -26.4% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $3.71M | -15.2% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $3.71M | -26.0% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $3.83M | +12.4% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $4.47M | -24.2% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $4.38M | -48.5% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $5.01M | -20.4% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $3.41M | -38.0% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $5.90M | +11.3% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $8.50M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $6.30M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $5.50M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $5.30M | – |
See a number that looks wrong?